Given these results, the DKK2 blockade can be used with anti-VEGFR therapy and even suboptimal doses of anti-VEGFR would provide additional benefits to the immunomodulatory effects of DKK2 blockade in treating colon tumors. The gene discussed is KDR; the disease is colonic neoplasm.